<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217291</url>
  </required_header>
  <id_info>
    <org_study_id>SY004003</org_study_id>
    <nct_id>NCT04217291</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study
      in patients with type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      200 cases will be included and divided into four groups with 50 cases in each group
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Glycosylated Hemoglobin A1c (HbA1c)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes in Glycosylated Hemoglobin A1c relative to baseline at 16 weeks compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects whose Glycosylated Hemoglobin A1c (HbA1c) was less than 7%.</measure>
    <time_frame>16 weeks</time_frame>
    <description>At the end of 16 weeks, the proportion of subjects whose Glycosylated Hemoglobin A1c was less than 7% .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with Glycosylated Hemoglobin A1c (HbA1c) &lt; 6.5%</measure>
    <time_frame>16 weeks</time_frame>
    <description>The proportion of subjects with Glycosylated Hemoglobin A1c &lt; 6.5% at 16 weeks after administration of SY-004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glycosylated Hemoglobin A1c (HbA1c)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change of Glycosylated Hemoglobin A1c relative to the baseline after 8 weeks of treatment with SY-004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects whose Glycosylated Hemoglobin A1c (HbA1c) was less than 7%</measure>
    <time_frame>8 weeks</time_frame>
    <description>At the end of 8 weeks, the proportion of subjects whose Glycosylated Hemoglobin A1c was less than 7% .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with Glycosylated Hemoglobin A1c (HbA1c) &lt; 6.5%</measure>
    <time_frame>8 weeks</time_frame>
    <description>The proportion of subjects with Glycosylated Hemoglobin A1c &lt; 6.5% at the end of 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood glucose (FPG) relative to the baseline</measure>
    <time_frame>1、2、4、8、12、16weeks</time_frame>
    <description>Changes in fasting blood glucose (FPG) relative to the baseline at 1, 2, 4, 8, 12 and 16 weeks after administration of SY-004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in postprandial blood glucose auc0-2h</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes in postprandial blood glucose auc0-2h ( 0-2h blood glucose AUC of Mixed-Meal-Tolerance-Test ) relative to baseline at 16 weeks after administration of SY-004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in abdominal weight relative to baseline at 8 and 16 weeks.</measure>
    <time_frame>8、16weeks</time_frame>
    <description>Changes in abdominal weight relative to baseline at 8 and 16 weeks after administration of SY-004.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SY-004-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a dose of 80mg/day taken orally for two weeks, and a dose of 80mg/day for 14 weeks from the third week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-004-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a dose of 80mg/day taken orally for two weeks, and a dose of 160mg/day for 14 weeks from the third week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-004-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a dose of 80mg/day orally in the first week, a dose of 160mg/day in the second week and a dose of 240mg/day for 14 weeks from the third week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a dose of SY-004 matching placebo taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-004</intervention_name>
    <description>Take orally once a day</description>
    <arm_group_label>SY-004-1</arm_group_label>
    <arm_group_label>SY-004-2</arm_group_label>
    <arm_group_label>SY-004-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SY-004 matching placebo</intervention_name>
    <description>Take orally once a day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender is not limited.

          -  Age at screening: ≥ 18 years old, ≥ 75 years old.

          -  According to WHO diagnostic criteria and classification in 1999, type 2 diabetes was
             diagnosed, with a course of at least 3 months.

          -  During screening and before randomization, 18kg / m2 ≤ BMI ≤ 35kg / m2.

          -  At the time of screening, they had been treated with diet or exercise for at least 3
             months.

          -  No antidiabetic drugs were used at the time of screening, or the antidiabetic drugs
             were used irregularly within 3 months before screening (the cumulative use of
             antidiabetic drugs in the past 3 months was no more than 2 weeks and no antidiabetic
             drugs were used in the past 1 month).

          -  During screening, 7% of the samples detected by local laboratory were ≤ HbA1c ≤ 11%.

          -  Before randomization, the central laboratory tested 7% ≤ HbA1c ≤ 11%.

          -  Fasting blood glucose (FBG) of 7-13.3 mmol / L (including boundary value) was measured
             in the central laboratory before randomization.

          -  The subjects must have informed consent before the study, and signed the written
             informed consent voluntarily.

          -  The subjects were willing and able to use the home blood glucose meter for self blood
             glucose monitoring.

          -  The subjects were able to communicate well with the researchers and complete the study
             according to the protocol.

        Exclusion Criteria:

          -  Staff members and their immediate family members of the research project. Lineal
             relatives refer to persons with consanguineous or legal relationships, including
             spouses, parents, children, brothers and sisters.

          -  Any of the following drugs or treatments were used prior to screening:

               1. In the past six months, insulin therapy has been used for more than one month, or
                  insulin therapy is needed at present.

               2. Long acting GLP-1 has been used in the past 6 months.

               3. Glucokinase activator (GKA) was used in the past 6 months.

               4. In the past 6 months, I have received weight-loss drugs or any weight-loss
                  treatment (such as surgery, excessive diet and exercise therapy) that leads to
                  weight instability.

               5. Participated in clinical trials of any drug or medical device in the past 3
                  months.

               6. Other drugs that may affect blood glucose metabolism have been used in the past 8
                  weeks, including growth hormone treatment, and long-term or repeated intermittent
                  systemic glucocorticoids (intravenous, oral or intra-articular administration for
                  more than 2 weeks or repeated courses, except inhalation or local external use),
                  etc.

               7. Strong CYP3A inducers or strong CYP3A inhibitors have been used in the past two
                  weeks or are planned to be used in the near future (refer to appendix 12.5.1).

               8. Drugs that are likely to cause torsade de pointes have been used in the past two
                  weeks or planned in the near future (refer to appendix 12.5.2).

          -  Prior to screening, there was a history or evidence of any of the following diseases:

               1. Type 1 diabetes, special type diabetes and secondary diabetes.

               2. Significant clinical cardiovascular events have occurred in the past 6 months
                  (refer to appendix 12.3).

               3. Patients with clinically significant peripheral vascular lesions, such as
                  ischemic ulcer or gangrene, diabetic foot ulcer and infection.

               4. There is sufficient evidence for the presence of active diabetic proliferative
                  retinopathy or maculopathy that is unstable or in need of treatment.

               5. there are obvious autonomic neuropathy, such as urinary retention, orthostatic
                  hypotension, diabetic diarrhea or gastroparesis.

               6. Have a history of acute or chronic pancreatitis.

               7. Ketoacidosis, diabetic acidosis or hyperosmolar nonketotic coma have occurred in
                  the past 6 months and need to be hospitalized.

               8. In the past 6 months, serious hypoglycemic events with unknown causes (need other
                  people's help to recover); or frequent hypoglycemia: for example, more than two
                  hypoglycemic events (blood glucose ≤ 3.9mmol / L) occurred in the first month
                  before screening.

               9. Any endocrine system disease related to blood glucose (such as hyperthyroidism,
                  acromegaly, Cushing's syndrome), immune system disease or other diseases that are
                  unstable or need treatment are not suitable for the study according to the
                  judgment of researchers.

              10. Have other diseases that affect glucose metabolism or are taking drugs that
                  significantly affect glucose metabolism.

              11. Severe trauma or acute infection that may affect blood glucose control has
                  occurred in the past month.

              12. Suffer from serious cardiovascular disease, respiratory system disease,
                  gastrointestinal disease, liver dysfunction, renal dysfunction, endocrine disease
                  (except diabetes), blood system disease, nervous system disease, and the disease
                  status can significantly change the absorption, distribution, metabolism and
                  excretion of the test drug, or taking the test drug will increase the risk of the
                  subject or affect the analysis of the research results.

              13. There are any types of malignant tumors (whether cured or not).

              14. A history of diseases that may cause hemolysis or red blood cell instability that
                  affect HbA1c detection, such as hemoglobinopathy (such as sickle cell anemia or
                  thalassemia, ferriblastic anemia).

              15. History of alcohol and drug abuse. Drink more than 21 units (male) or 14 units
                  (female) of alcohol per week (1 unit is about 360 ml of beer or 45 ml of spirits
                  or 150 ml of wine with 40% alcohol).

              16. There are mental or nervous system diseases, unwillingness to communicate or
                  language barriers, and insufficient understanding and cooperation.

          -  There is any laboratory inspection index meeting the following standards at screening
             or random:

               1. In the absence of pacemaker, 12 lead ECG showed second or third degree
                  atrioventricular block, or corrected qtcb &gt; 450ms (male) or &gt; 470ms (female).

               2. eGFR&lt;60ml/(min•1.73m2)。

               3. ALT &gt; 1.5 times the upper limit of normal value (× ULN), AST &gt; 1.5 × ULN, TBIL &gt;
                  1.5 × ULN.

               4. Hypertension (systolic blood pressure ≥ 160mmhg or diastolic blood pressure ≥
                  100mmhg) that cannot be controlled by drugs or other treatment means exists.

               5. Hypertriglyceridemia (triglyceride &gt; 500mg / dl (5.70mmol / L)) was found which
                  could not be controlled by drugs or other treatments.

               6. Hemoglobin &lt; 90g / L.

               7. The serological evidence of infectious virus is positive, including hepatitis B,
                  hepatitis C, HIV and Treponema pallidum.

               8. Fasting C-peptide &lt; 1.0 ng / ml (333 pmol / L).

          -  Fertile eligible subjects (men and women) disagreed with the use of reliable
             contraceptive methods during the study and at least one month after the last
             administration.

          -  Pregnant or lactating women.

          -  Allergic to the active ingredient agratine hydrochloride, or severe allergic
             constitution / severe allergic history.

          -  Other circumstances judged by the sponsor or researcher as unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiming Mu, Dr.</last_name>
    <phone>010-55499001</phone>
    <email>muyiming@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yiming Mu, Dr.</last_name>
      <phone>010-55499001</phone>
      <email>muyiming@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

